United States: CMS To Test Value-Based Insurance Design In Medicare Advantage

While CMS's demonstration model will allow for reduced cost sharing and other benefit design elements to encourage targeted use of high-value clinical services, Medicare Advantage Organizations should be aware of certain inherent legal risks.

On September 1, 2015, the Centers for Medicare & Medicaid Services (CMS) announced the Medicare Advantage Value-Based Insurance Design Model (Model). Medicare Advantage (MA) Organizations operating in Arizona, Indiana, Iowa, Massachusetts, Oregon, Pennsylvania and Tennessee may apply to use reduced cost-sharing and/or supplemental benefits to encourage enrollees with one or more of seven targeted chronic conditions to consume higher value health care services. Specifically, CMS will allow participating MA Organizations to propose specific interventions for enrollees in one or more CMS-identified chronic disease categories that involve (i) reduced cost sharing for high value services, (ii) reduced cost sharing for high value providers, (iii) reduced cost sharing for enrollees participating in disease management or related programs or (iv) coverage of additional supplemental benefits (collectively, VBID Interventions).

The five-year Model, which begins on January 1, 2017, represents CMS's first effort to experiment with value-based insurance design (VBID). While VBID has gained increasing recognition in the commercial market, its clinically nuanced approach has been limited across Medicare programs due to various legal barriers, including the so-called "uniform benefit" requirement. While CMS attempts to provide a pathway forward through the MA regulations, the Model presents certain legal risks about which MA Organizations should be aware.

MA Organization Eligibility

To be eligible to participate in the Model in one of the seven test states, an MA Organization must:

  • Be a health maintenance organization (HMO), HMO-point-of service (HMO-POS), or local preferred provider organization (PPO) plan;
  • Have all or a portion of its service area within one of the model test states;
  • Have at least 2,000 enrollees and at least 50 percent of its total enrollment in the model test states;
  • Not be offered in more than two states total;
  • Have been offered in at least three annual open enrollment periods prior to the CY 2017 open enrollment period; and
  • Have least a three-star overall quality rating for CY 2015.

MA Organizations must implement VBID Interventions in all counties/segments for the MA Plan (but are not required to offer VBID Interventions throughout all of their MA Plans). If a MA Plan covers counties or segments that are both inside and outside of a test state, the MA Organization must provide VBID Interventions to all of the Model-participating enrollees in the MA Plan, regardless of whether they reside inside or outside of the state.

CMS will accept all qualified applicants submitting "acceptable" proposals within a test state.

Context of the Model

VBID seeks to minimize over- and underuse of certain health care services by aligning patients' financial interests, such as their copays and deductibles, with the clinical value of the services they receive. The approach builds on behavioral economics by aiming to reduce barriers to high-value treatments and discourage low-value treatments through cost-sharing differentials.

As Medicare fee-for-service (FFS) relies on a "one-size-fits-all" approach, the program generally cannot lower cost-sharing levels for clinically recommended services or across provider types. Further, approximately 85 percent of Medicare FFS beneficiaries have some form of supplemental insurance coverage that already reduces or eliminates their cost sharing, thus mitigating the opportunity to influence Medicare FFS beneficiary behavior. By contrast, the MA Program has been heralded to offer a key forum to test VBID in federal healthcare programs (see also H.R. 2570, "Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act of 2015" and S. 1396, "Value-Based Insurance Design Seniors Copayment Reduction Act of 2015"), due in part to the broad array of tools that MA Organizations can leverage to promote evidence-based care, including network formation; provider-oriented strategies, such as quality and performance bonuses; and utilization management programs.

Various MA Program requirements currently impede opportunities to use VBID, however. While premiums and benefits (including cost-sharing) may vary among MA Plans, by law all members enrolled in the same MA Plan must receive the same benefits with the same cost-sharing at the same premium. Under the Model, CMS would waive certain uniform benefits requirements (along with certain communications, disclosures and marketing requirements) as necessary to implement the Model, enabling MA Organizations to differentiate among enrollees in the same MA Plan and to tailor benefit designs to certain enrollee segments based on their health status. (The Model does not, however, address potential discrimination issues for Model-participating or Model-excluded members.) The guidance hints that waivers of certain fraud and abuse barriers may be forthcoming (such as for the so-called "beneficiary inducement prohibition under SSA § 1128A), but provides no details as to what may be proposed or when.

Design of the Model and VBID Interventions

The Model is designed to test the hypothesis that clinically nuanced VBID approaches will (i) increase enrollee satisfaction, (ii) improve enrollee clinical outcomes, (iii) reduce plan expenditures and (iv) lower plan bids.

CMS will require that participating MA Organizations make VBID Interventions available to all enrollees who qualify in one or more selected chronic condition populations. The Model currently is limited to seven chronic conditions: diabetes, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, past stroke, hypertension and mood disorders. CMS has designated qualifying ICD-10 codes and will provide strict criteria to assist participating MA Organizations with identifying all enrollees who fall into selected chronic condition categories.  CMS will conduct retrospective audits to determine if "all VBID-eligible enrollees actually received the VBID interventions." (emphasis added)

MA Organizations may employ one or more of the following VBID Interventions targeted to the selected chronic condition population(s) under the Model:

  1. Reduce or eliminate cost-sharing for "high-value" items or services, including covered Medicare Part D drugs. An MA Organization will be required to clearly identify such items or services in advance. It may elect to eliminate or reduce copays or coinsurance, or may exempt a given item or service from the plan deductible.
  2. Reduce or eliminate cost-sharing for high-value health care providers broadly or when delivering a particular high-value service. An MA Organization must propose a clinically-based methodology to identify specific high-value providers for the selected population for advance CMS approval. High-value providers may be selected from all Medicare provider types, including but not limited to, physicians/practices, hospitals, skilled nursing facilities, home health agencies and ambulatory surgical centers. CMS encourages MA Organizations to apply independent external metrics to evaluate whether a particular provider is high value and will permit cost or efficiency to be included in selection criteria if combined with relevant quality measures.
  3. Reduce cost-sharing for enrollees who participate in disease-management or related programs. An MA Organization may propose to condition cost-sharing reductions on an enrollee meeting defined participation milestones, contingent on the proposal's approval by CMS. The MA Organization may not structure milestones around the achievement of clinical goals and must provide all enrollees in the selected population with the opportunity to participate regardless of health status, location, or disability.
  4. Coverage of certain supplemental benefits solely for targeted chronic conditions. As examples, CMS cites telemedicine, non-emergency transportation to primary care visits, meals and counseling programs, among other services, that have clinical justifications for a selected population. An MA Organization would be required to fund these targeted supplemental benefits through "rebates" and/or premium dollars paid by all enrollees.

For bid purposes, CMS will count all VBID Interventions as mandatory supplemental benefits rather than as part of the basic benefit. CMS also will require MA Organizations to submit actuarially certified financial projections of the VBID Interventions on plan medical utilization, cost, and premiums and to demonstrate net savings for CMS over the five-year term of the Model. These projections must be incorporated into the MA Organization's bid and annually updated to incorporate any new selected chronic conditions as well as actual historical experience.

Legal and Practical Implications:

  • Enrollee Confusion and Related Claims. MA Organizations will have to use caution to ensure that VBID Interventions do not create enrollee confusion. Specifically, MA Organizations should ensure that VBID Interventions involving waivers or reductions of cost-sharing for high-value services attach to clearly defined episodes of care, and do not result in unexpected enrollee costs as a result of a provider's choice of coding, facility fees or non-discounted services from other providers. While CMS will require prior review of VBID Intervention proposals to guard against adverse effects, this action will not insulate MA Organizations from potential enrollee claims related to the design or implementation of the VBID Interventions in the MA Plan. Transportation to and from primary care visits, for example, is a benefit that all enrollees, regardless of their health status, may wish to enjoy. Enrollees denied access to such a benefit based on their health status (i.e., lack of a specific condition) may challenge such an approach.
  • Compliance with Anti-Discrimination Requirements. CMS elected not to waive any legal provisions pertaining to anti-discrimination under the Model, meaning that MA Organizations must ensure that they structure VBID Interventions in a manner that does not indirectly discriminate against Model-participating or Model-excluded enrollees. CMS has indicated that MA Organizations, for example, must ensure that VBID Interventions are not coupled with changes to the MA Plan at large in a manner that decreases the benefits available to enrollees that have non-targeted clinical conditions. Similarly, in Intervention #2, while CMS does not propose to require specific network adequacy or access standards around a MA Organization's selection of high-value providers, it has observed that certain patterns of inaccessibility could constitute discrimination.
  • Provider Challenges. Providers not selected as high-value providers under Intervention #2 may attempt to bring contractual, defamation or libel, or other claims against the MA Organization for exclusion from the high-value provider sub-network, especially should these providers experience subsequent patient loss to competitors who receive a high-value designation. This challenge may be particularly acute in instances where providers previously contracted to be in the most favorable tier of the MA Organization's benefit design, but are not designated as "high value" in the Model as they do not meet the criteria adopted by the MA Organization and approved by CMS. MA Organizations also may experience challenges around the methodologies and data they use to determine "high value." While CMS will require prior review of such methodologies, it has not suggested that MA Organizations will receive any special protection against legal challenges they may face. Additionally, while non-Medicare-eligible providers may engage in VBID Interventions broadly, it appears that they will not be able to be designated as high-value providers under Intervention #2, regardless of their potential to deliver high-quality, efficient care.
  • Missed Opportunities. Notwithstanding CMS's significant policy rationale, CMS's dual prohibitions against (i) increasing cost-sharing for low-value items and services and (ii) linking cost sharing reductions to the achievement of specific clinical goals inherently limit a level of patient engagement and indirectly expose aspects of CMS's model design that may create risks for individual MA Plans. As an MA Organization must harbor the costs of all VBID Interventions they provide to enrollees under the Model, an MA Organization either will need to experience a relatively immediate return on investment from its VBID Interventions or recoup such expenses elsewhere in the plan benefit package (in compliance with non-discrimination requirements) or it will risk needing to increase its bid. Notably, the inability of MA Organizations to concomitantly reduce cost sharing for high-value items and services while increasing cost sharing for low-value items and services belies a large and growing body of materials identifying evidence-based, low-value interventions, such as those compiled by the American Board of Internal Medicine's Choosing Wisely Campaign.

Plan Marketing and Enrollee Communication Requirements

Under the Model, an MA Organization will be required to send all targeted enrollees written materials summarizing VBID Intervention benefits (i) at the beginning of each model year, (ii) when an enrollee became newly eligible or (iii) with the Annual Notice of Change and Evidence of Coverage mailing for new enrollees.  CMS also anticipates that MA Organizations will engage in regular follow-up communications with targeted enrollees, which CMS may subject to prior review.

CMS will continue to require compliance with all MA marketing regulations and guidance. Participating MA Organizations will be prohibited from mentioning VBID Interventions in pre-enrollment marketing, but will be able to disseminate information about VBID Interventions when a potential enrollee makes a specific inquiry. Further, CMS will issue guidance to non-participating organizations, limiting their communications about the Model.

Legal and Practical Implications:

  • As MA Organizations are required to notify all enrollees eligible for the Model upon receipt of a claim that reflects a defined diagnosis, MA Organizations may experience a rise in member complaints about privacy and the unanticipated use of their personal health information. Notwithstanding CMS's motivations for limiting broader communication by MA Organizations, the potential for enrollees to react poorly based on their own privacy expectations, even if misplaced, is a practical implication. Relatedly, MA Organizations will need to have appropriately designed operational systems to implement CMS's enrollee notification requirements in a timely fashion.
  • While CMS states that it does not want to encourage or discourage enrollment in MA or any specific MA Plan, the Model's requirements that communications be triggered only when a potential enrollee makes a specific inquiry, may compound enrollee confusion, particularly when combined with probable communication among MA enrollees in selected test states.


CMS's MA VBID Model represents a critical opportunity for MA Organizations in the seven selected states to engage in VBID for high-risk populations and will shape future flexibilities for VBID in the MA market at large. MA Organizations in eligible states should closely consider certain legal risks as they evaluate this opportunity and as they design and implement their VBID Intervention proposals.

While the Model is narrowly focused on testing VBID Interventions, CMS has signaled that it may unveil a broader suite of targeted MA models offering various regulatory flexibilities, including the use of remote access technologies and/or the integration of hospice care benefits concurrently with curative care in the basic benefit package.

CMS plans to release the Request for Applications for the Model later this month, with responses due November 2015. CMS will hold an introductory webinar on the Model on September 24, 2015.

CMS To Test Value-Based Insurance Design In Medicare Advantage

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.